Compare RKDA & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | CDT |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | 8 | 6 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 22.1M |
| IPO Year | 2015 | N/A |
| Metric | RKDA | CDT |
|---|---|---|
| Price | $1.04 | $1.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.9K | ★ 50.8K |
| Earning Date | 05-07-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,858,000.00 | N/A |
| Revenue This Year | $61.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.89 | $0.37 |
| 52 Week High | $6.71 | $11.00 |
| Indicator | RKDA | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 27.77 | 39.44 |
| Support Level | $0.89 | $1.54 |
| Resistance Level | $1.26 | $2.30 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 11.63 | 1.06 |
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.